Outcome of the meeting of the Board of Directors of the Company held on August 17, 2026

Novartis India Limited August 17, 2026 The Secretary, BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001. Scrip Code: 500672 Sub: Outcome of the Meeting of the Board of Directors of Novartis India Limited (“the Company”) held on Monday, August 17, 2026. Dear Sir/ Madam, Pursuant to Regulations 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’) read with the relevant circulars issued by SEBI (‘SEBI Circular’), we hereby inform that the Board of Directors (‘Board’) of the Company in their Meeting held today i.e. Monday, August 17, 2026, inter-alia have considered and approved the following: 1. adoption of new set of Memorandum of Association of the Company inter-alia, to align them with the provisions of Table A of Schedule I of the Companies Act, 2013, subject to the approval of the shareholders at the ensuing Annual General Meeting of the Company. 2. proposal for change of name of the Company and consequential alteration of the Memorandum and Articles of Association, pursuant to the approval received from the Central Registration Centre (CRC) and subject to shareholders’ approval at the ensuing Annual General Meeting. 3. amendment to the Notice of the 78th Annual General Meeting ("AGM"), approved by the Board at its meeting held on August 7, 2026. The said Meeting commenced at 07:15 P.M. (IST) and concluded at 07:30 P.M. (IST). The above is for your information and the same is also available on the website of the Company i.e. www.nilpharma.co.in Yours sincerely, For Novartis India Limited Chandni Maru Company Secretary and Compliance Officer A60291 Registered Office: Inspire BKC, 7th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India. CIN: L24200MH1947PLC006104 | Tel: +91 22 50243000 Email: investor.relations@nilpharma.co.in | Website: www.nilpharma.co.in